Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
GHDX's Cash-to-Debt is ranked higher than
99% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. GHDX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GHDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.9  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.80
GHDX's Equity-to-Asset is ranked higher than
79% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. GHDX: 0.80 )
Ranked among companies with meaningful Equity-to-Asset only.
GHDX' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.56  Med: 0.8 Max: 0.89
Current: 0.8
-3.56
0.89
Interest Coverage No Debt
GHDX's Interest Coverage is ranked higher than
99% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. GHDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GHDX' s Interest Coverage Range Over the Past 10 Years
Min: 80.08  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 7
Altman Z-Score: 16.41
Beneish M-Score: -1.98
WACC vs ROIC
4.91%
7.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -2.24
GHDX's Operating Margin % is ranked lower than
55% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. GHDX: -2.24 )
Ranked among companies with meaningful Operating Margin % only.
GHDX' s Operating Margin % Range Over the Past 10 Years
Min: -46.33  Med: -5.5 Max: 4.01
Current: -2.24
-46.33
4.01
Net Margin % -1.50
GHDX's Net Margin % is ranked lower than
51% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. GHDX: -1.50 )
Ranked among companies with meaningful Net Margin % only.
GHDX' s Net Margin % Range Over the Past 10 Years
Min: -42.63  Med: -5.59 Max: 3.81
Current: -1.5
-42.63
3.81
ROE % -3.25
GHDX's ROE % is ranked lower than
52% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. GHDX: -3.25 )
Ranked among companies with meaningful ROE % only.
GHDX' s ROE % Range Over the Past 10 Years
Min: -48.31  Med: -11.7 Max: 7.79
Current: -3.25
-48.31
7.79
ROA % -2.54
GHDX's ROA % is ranked higher than
50% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. GHDX: -2.54 )
Ranked among companies with meaningful ROA % only.
GHDX' s ROA % Range Over the Past 10 Years
Min: -37.4  Med: -9.24 Max: 6.18
Current: -2.54
-37.4
6.18
ROC (Joel Greenblatt) % -14.70
GHDX's ROC (Joel Greenblatt) % is ranked lower than
53% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. GHDX: -14.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GHDX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -299.12  Med: -55.36 Max: 74.51
Current: -14.7
-299.12
74.51
3-Year Revenue Growth Rate 4.80
GHDX's 3-Year Revenue Growth Rate is ranked lower than
51% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. GHDX: 4.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GHDX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.6 Max: 136.5
Current: 4.8
0
136.5
3-Year EBITDA Growth Rate 2.50
GHDX's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. GHDX: 2.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GHDX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -59.8  Med: -54.7 Max: 2.5
Current: 2.5
-59.8
2.5
GuruFocus has detected 2 Warning Signs with Genomic Health Inc GHDX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GHDX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

GHDX Guru Trades in Q3 2016

Columbia Wanger 468,556 sh (New)
Jim Simons 547,600 sh (+25.57%)
Chuck Royce 68,500 sh (-22.60%)
Paul Tudor Jones 7,600 sh (-35.59%)
» More
Q4 2016

GHDX Guru Trades in Q4 2016

Columbia Wanger 1,275,338 sh (+172.18%)
Jim Simons 576,700 sh (+5.31%)
Paul Tudor Jones Sold Out
Chuck Royce 1,200 sh (-98.25%)
» More
Q1 2017

GHDX Guru Trades in Q1 2017

Jim Simons 733,200 sh (+27.14%)
Columbia Wanger 1,607,649 sh (+26.06%)
Chuck Royce 1,200 sh (unchged)
» More
Q2 2017

GHDX Guru Trades in Q2 2017

Jim Simons 813,300 sh (+10.92%)
Chuck Royce 1,200 sh (unchged)
Columbia Wanger 1,435,395 sh (-10.71%)
» More
» Details

Insider Trades

Latest Guru Trades with GHDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:BEAT, SZSE:300685, SZSE:300439, NAS:ALOG, NSE:LALPATHLAB, NAS:ABAX, NAS:NRCIA, SHSE:600055, NAS:MEDP, HKSE:02393, NAS:AXDX, SHSE:603108, NAS:KANG, NAS:VREX, TSE:4694, NAS:NEO, TSE:4282, SZSE:300396, NAS:FMI, NAS:QDEL » details
Traded in other countries:G7H.Germany,
Headquarter Location:USA
Genomic Health Inc is a healthcare company. It provides genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer.

Genomic Health Inc is a healthcare company. It provides genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer.

Top Ranked Articles about Genomic Health Inc

Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017
Genomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 Congress
Genomic Health to Present at the 2017 Wells Fargo Healthcare Conference
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score™ Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9, 2017
Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress
Genomic Health to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017
Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer
Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX® Tests to Optimize Outcomes in Patients Across Cancer Types
Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types

Ratios

vs
industry
vs
history
Forward PE Ratio 73.53
GHDX's Forward PE Ratio is ranked lower than
100% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. GHDX: 73.53 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 6.82
GHDX's PB Ratio is ranked lower than
74% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. GHDX: 6.82 )
Ranked among companies with meaningful PB Ratio only.
GHDX' s PB Ratio Range Over the Past 10 Years
Min: 4.81  Med: 7.03 Max: 14.28
Current: 6.82
4.81
14.28
PS Ratio 3.40
GHDX's PS Ratio is ranked higher than
54% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. GHDX: 3.40 )
Ranked among companies with meaningful PS Ratio only.
GHDX' s PS Ratio Range Over the Past 10 Years
Min: 2.17  Med: 3.78 Max: 20.45
Current: 3.4
2.17
20.45
Price-to-Free-Cash-Flow 466.11
GHDX's Price-to-Free-Cash-Flow is ranked lower than
97% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. GHDX: 466.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GHDX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 34.46  Med: 73.71 Max: 14545
Current: 466.11
34.46
14545
Price-to-Operating-Cash-Flow 48.49
GHDX's Price-to-Operating-Cash-Flow is ranked lower than
82% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. GHDX: 48.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GHDX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 27.44  Med: 49.19 Max: 1560.53
Current: 48.49
27.44
1560.53
EV-to-EBIT -140.49
GHDX's EV-to-EBIT is ranked lower than
99.99% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. GHDX: -140.49 )
Ranked among companies with meaningful EV-to-EBIT only.
GHDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -791  Med: -23.6 Max: 514.8
Current: -140.49
-791
514.8
EV-to-EBITDA 419.98
GHDX's EV-to-EBITDA is ranked lower than
99% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. GHDX: 419.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
GHDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3540.2  Med: -20.65 Max: 939.6
Current: 419.98
-3540.2
939.6
EV-to-Revenue 3.16
GHDX's EV-to-Revenue is ranked higher than
63% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. GHDX: 3.16 )
Ranked among companies with meaningful EV-to-Revenue only.
GHDX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8  Med: 3.4 Max: 19.2
Current: 3.16
1.8
19.2
Current Ratio 3.95
GHDX's Current Ratio is ranked higher than
69% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. GHDX: 3.95 )
Ranked among companies with meaningful Current Ratio only.
GHDX' s Current Ratio Range Over the Past 10 Years
Min: 3.26  Med: 4.5 Max: 15.83
Current: 3.95
3.26
15.83
Quick Ratio 3.95
GHDX's Quick Ratio is ranked higher than
72% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. GHDX: 3.95 )
Ranked among companies with meaningful Quick Ratio only.
GHDX' s Quick Ratio Range Over the Past 10 Years
Min: 3.26  Med: 4.5 Max: 15.83
Current: 3.95
3.26
15.83
Days Sales Outstanding 35.39
GHDX's Days Sales Outstanding is ranked higher than
83% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. GHDX: 35.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
GHDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.15  Med: 35.94 Max: 47.19
Current: 35.39
27.15
47.19
Days Payable 36.17
GHDX's Days Payable is ranked lower than
70% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. GHDX: 36.17 )
Ranked among companies with meaningful Days Payable only.
GHDX' s Days Payable Range Over the Past 10 Years
Min: 14.62  Med: 43.28 Max: 75.79
Current: 36.17
14.62
75.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.00
GHDX's 3-Year Average Share Buyback Ratio is ranked higher than
67% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. GHDX: -3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GHDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -197.9  Med: -3.1 Max: -1
Current: -3
-197.9
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 17.39
GHDX's Price-to-Net-Cash is ranked lower than
61% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.00 vs. GHDX: 17.39 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GHDX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.64  Med: 12.35 Max: 23.16
Current: 17.39
3.64
23.16
Price-to-Net-Current-Asset-Value 10.42
GHDX's Price-to-Net-Current-Asset-Value is ranked lower than
54% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.01 vs. GHDX: 10.42 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GHDX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.53  Med: 8.62 Max: 17
Current: 10.42
3.53
17
Price-to-Tangible-Book 6.84
GHDX's Price-to-Tangible-Book is ranked lower than
56% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.57 vs. GHDX: 6.84 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GHDX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.3  Med: 6.71 Max: 11.76
Current: 6.84
3.3
11.76
Price-to-Intrinsic-Value-Projected-FCF 10.76
GHDX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
92% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. GHDX: 10.76 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GHDX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.19  Med: 6.25 Max: 38.47
Current: 10.76
4.19
38.47
Price-to-Median-PS-Value 0.90
GHDX's Price-to-Median-PS-Value is ranked higher than
64% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. GHDX: 0.90 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GHDX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.6  Med: 1 Max: 4.19
Current: 0.9
0.6
4.19
Earnings Yield (Greenblatt) % -0.73
GHDX's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. GHDX: -0.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GHDX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8.9  Med: -2.05 Max: 1.3
Current: -0.73
-8.9
1.3

More Statistics

Revenue (TTM) (Mil) $334.47
EPS (TTM) $ -0.14
Beta0.43
Short Percentage of Float5.65%
52-Week Range $26.37 - 33.97
Shares Outstanding (Mil)34.65

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 347 391 428
EPS ($) -0.20 0.45 0.79
EPS without NRI ($) -0.20 0.45 0.79
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}